Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models.
cancer diagnostics
drug sensitivity testing
functional precision medicine
molecular tumor board
patient stratification
Journal
Trends in pharmacological sciences
ISSN: 1873-3735
Titre abrégé: Trends Pharmacol Sci
Pays: England
ID NLM: 7906158
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
13
05
2022
revised:
20
08
2022
accepted:
22
08
2022
pubmed:
27
9
2022
medline:
19
10
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
Functional precision medicine is a new, emerging area that can guide cancer treatment by capturing information from direct perturbations of tumor-derived, living cells, such as by drug sensitivity screening. Precision cancer medicine as currently implemented in clinical practice has been driven by genomics, and current molecular tumor boards rely extensively on genomic characterization to advise on therapeutic interventions. However, genomic biomarkers can only guide treatment decisions for a fraction of the patients. In this review we provide an overview of the current state of functional precision medicine, highlight advances for drug-sensitivity screening enabled by cell culture models, and discuss how artificial intelligence (AI) can be coupled to functional precision medicine to guide patient stratification.
Identifiants
pubmed: 36163057
pii: S0165-6147(22)00195-X
doi: 10.1016/j.tips.2022.08.009
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-985Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S.S.S. has received honoraria from AbbVie and AstraZeneca, and research support from BeiGene and TG Therapeutics. Å.F. has received honoraria from Bayer, Novartis, Pierre Fabre, Amgen, and Pfizer. The other authors declare no conflicts of interest.